France Will Now Pay for Wegovy and Mounjaro Obesity Drugs. But There’s a Catch
It’s official. Starting mid-June, the French state will partially reimburse the cost of Wegovy and Mounjaro, two of the most popular weight-loss injections in the world, for patients with severe or morbid obesity.
Health Minister Stéphanie Rist announced the scheme the same day, and the formal legislation hit the Journal officiel the morning after.
These drugs cost around €300 a month out of pocket. For a lot of families, that’s simply not possible.
Who Qualifies
The reimbursement doesn’t cover everyone who wants to lose weight. France is keeping this tightly targeted.
Eligible patients are adults with either massive obesity without other health conditions, or severe obesity with associated conditions like diabetes or cardiovascular disease.
That’s essentially the population that would otherwise be considered for bariatric surgery.
About one million people in France fall into this category.
The official reimbursement rate is 65%. But Minister Rist pointed out that in practice, nearly all eligible patients already receive 100% healthcare coverage due to the severity of their condition.
For most of them, these injections will cost nothing starting next month.
The €300-a-Month Problem
Wegovy, made by Danish pharmaceutical company Novo Nordisk, and Mounjaro, made by American firm Eli Lilly, are both GLP-1 receptor agonists.
They work by mimicking a hormone that regulates appetite, making people feel full sooner and eat less.
They work, that’s not really in dispute. The dispute has always been about the price.
In France, patients have been paying between €270 and €330 a month since the drugs became available on prescription in 2024.
That’s roughly $360 at current exchange rates. In the United States, Wegovy’s list price without insurance is around $1,349 a month – though most Americans with coverage pay far less.
France spent two years watching demand build before acting. As of late January 2026, more than 70,000 patients were already using Mounjaro in France alone.
Why France Moved Now
Around 18% of the French population is classified as obese, about 10 million people. That’s according to a French study published in 2024 using European Medicines Authority criteria.
The Haute Autorité de Santé, France’s independent health authority, backed partial reimbursement back in December 2024, arguing it would save money overall by reducing the need for surgery, hospitalizations, and long-term diabetes care.
Anne-Sophie Joly, president of the National Collective of Obesity Associations, put it plainly to AFP:
“A disadvantaged family obviously cannot afford to spend more than €300 per month on medication when they are already struggling to make ends meet.”
Minister Rist framed the decision as prevention. Patients who access these drugs, she said, are people “who will no longer need surgery and who will have fewer health risks.”
The estimated annual cost to the French health system: around €100 million – modest, given the scale.
France Not Alone But Ahead
Several European countries already offer some form of reimbursement for GLP-1 weight-loss drugs. The UK, Switzerland, and Greece have partial or time-limited schemes in place.
The United States, by contrast, moved in the opposite direction earlier this year. The Trump administration rejected a Biden-era proposal that would have required Medicare and Medicaid to cover Wegovy and similar drugs for obesity.
As of now, federal coverage remains limited to diabetic patients and a narrow subset with obesity-related cardiovascular conditions.
France also announced an obesity plan running from 2026 to 2030 alongside the reimbursement. It combines medical follow-up, dietetic support, psychological care, and adapted physical activity for eligible patients.
Mounjaro is manufactured in France, at Eli Lilly’s facility in the country. The president of Eli Lilly France called Thursday’s decision a historic moment for French patients.